Turning immune cells into cancer-fighting ninjas
What if your own immune cells could be trained to fight off cancer? That's the idea behind cancer immunotherapy. Dr. Steven Rosenberg's group at the National Cancer Institute uses RetroNectin reagent to introduce T-cell receptor genes recognizing specific cancer antigens into a patient's own lymphocytes. These engineered cells are then returned to the patient, where they specifically target cancer cells expressing the antigen. That's GOOD Science!
Explore how we support research focused on improving human health
From sample prep and biomarker discovery to single-cell analysis, genetic and epigenetic analysis, HLA typing, T-cell therapy and profiling, gene editing, and antibody therapeutics: browse techniques and reagents for cancer research.
Cancer immunotherapy is a promising approach for cancer treatment and holds several key advantages over traditional therapies, including high specificity, little or no side effects, and a good safety profile.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.